HRP20161808T1 - Medicinska uporaba hvatača radikala i antioksidansa alfa-1-mikroglobulin - Google Patents
Medicinska uporaba hvatača radikala i antioksidansa alfa-1-mikroglobulin Download PDFInfo
- Publication number
- HRP20161808T1 HRP20161808T1 HRP20161808TT HRP20161808T HRP20161808T1 HR P20161808 T1 HRP20161808 T1 HR P20161808T1 HR P20161808T T HRP20161808T T HR P20161808TT HR P20161808 T HRP20161808 T HR P20161808T HR P20161808 T1 HRP20161808 T1 HR P20161808T1
- Authority
- HR
- Croatia
- Prior art keywords
- microglobulin
- alpha
- use according
- agents
- seq
- Prior art date
Links
- 101800001761 Alpha-1-microglobulin Proteins 0.000 title claims 21
- 102000003966 Alpha-1-microglobulin Human genes 0.000 title claims 21
- 239000003963 antioxidant agent Substances 0.000 title 1
- 230000003078 antioxidant effect Effects 0.000 title 1
- 239000002516 radical scavenger Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 101500025164 Homo sapiens Alpha-1-microglobulin Proteins 0.000 claims 2
- 239000012752 auxiliary agent Substances 0.000 claims 2
- 230000002255 enzymatic effect Effects 0.000 claims 2
- 230000036542 oxidative stress Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 230000002292 Radical scavenging effect Effects 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000004792 oxidative damage Effects 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
Claims (10)
1. Alfa-1-mikroglobulin za uporabu u liječenju ili profilaksi bolesti ili stanja koje uključuje oksidativni stres popravkom ili prevencijom oksidativne štete kombinacijom enzimskog smanjenja, ne-enzimskog smanjenja i hvatanja radikala, naznačen time da bolest ili stanje koje uključuje oksidativni stres je zatajenje bubrega povezano s dijalizom.
2. Alfa-1-mikroglobulin za uporabu prema zahtjevu 1, naznačen time da je bolest ili stanje povezano s prisutnošću slobodnog hemoglobina u tjelesnoj tekućini.
3. Alfa-1-mikroglobulin za uporabu prema zahtjevu 1 ili 2, naznačen time da alfa-1-mikroglobulin ima barem 60% identičnosti s ljudskim alfa-1-mikroglobulinom (SEQ NO: 1).
4. Alfa-1-mikroglobulin za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da alfa-1-mikroglobulin je ljudski alfa-1-mikroglobulin (SEQ NO: 1).
5. Alfa-1-mikroglobulin za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da alfa-1-mikroglobulin ima barem 60% identičnosti s ljudskim rekombinantnim alfa-1-mikroglobulinom (SEQ NO: 2).
6. Alfa-1-mikroglobulin za uporabu prema bilo kojem od zahtjeva 1-2, 5, naznačen time da alfa-1-mikroglobulin je ljudski rekombinantni alfa-1-mikroglobulin (SEQ ID NO: 2).
7. Alfa-1-mikroglobulin za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da se alfa-1-mikroglobulin primjenjuje parenteralno.
8. Alfa-1-mikroglobulin za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da se alfa-1-mikroglobulin primjenjuje lokalno npr. u tjelesnu šupljinu.
9. Alfa-1-mikroglobulin za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da se alfa-1-mikroglobulin primjenjuje u obliku pripravka koji sadrži alfa-1-mikroglobulin i farmaceutski prihvatljivo pomoćno sredstvo.
10. Alfa-1-mikroglobulin za uporabu prema zahtjevu 9, naznačen time da je farmaceutski prihvatljivo pomoćno sredstvo odabrano od otapala, sredstava za podešavanje pH, osmotski aktivnih sredstava, ko-otapala, sredstava za solubilizaciju, sredstva za emulgiranje, sredstva za suspendiranje, površinski aktivnih sredstava, sredstava za vlaženje.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13533808P | 2008-07-18 | 2008-07-18 | |
| DKPA200801024 | 2008-07-18 | ||
| US18938108P | 2008-08-18 | 2008-08-18 | |
| DKPA200801116 | 2008-08-18 | ||
| US19750608P | 2008-10-27 | 2008-10-27 | |
| DKPA200801478 | 2008-10-27 | ||
| EP13172049.2A EP2638915B1 (en) | 2008-07-18 | 2009-07-17 | Medical use of the radical scavenger and antioxidant alpha-1-microglobulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161808T1 true HRP20161808T1 (hr) | 2017-02-24 |
Family
ID=41550762
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160760TT HRP20160760T1 (hr) | 2008-07-18 | 2016-06-29 | Medicinska uporaba čistača radikala i antioksidacijskog alfa-1-mikroglobulina |
| HRP20161808TT HRP20161808T1 (hr) | 2008-07-18 | 2016-12-29 | Medicinska uporaba hvatača radikala i antioksidansa alfa-1-mikroglobulin |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160760TT HRP20160760T1 (hr) | 2008-07-18 | 2016-06-29 | Medicinska uporaba čistača radikala i antioksidacijskog alfa-1-mikroglobulina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10350268B2 (hr) |
| EP (2) | EP2313106B1 (hr) |
| JP (3) | JP5694928B2 (hr) |
| AU (1) | AU2009270435B2 (hr) |
| CA (1) | CA2730531A1 (hr) |
| DK (2) | DK2313106T3 (hr) |
| ES (2) | ES2571956T3 (hr) |
| HR (2) | HRP20160760T1 (hr) |
| HU (2) | HUE027953T2 (hr) |
| PL (2) | PL2313106T3 (hr) |
| PT (1) | PT2638915T (hr) |
| WO (1) | WO2010006809A2 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7932365B2 (en) | 2003-11-08 | 2011-04-26 | Pro Thera Biologics, Llc | Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
| AU2008214837B2 (en) | 2007-02-12 | 2013-01-10 | A1M Pharma Ab | Diagnosis and treatment of preeclampsia |
| AU2009260822B2 (en) | 2008-05-28 | 2016-09-22 | Prothera Biologics, Inc. | Preparation and composition of Inter-alpha inhibitor proteins from blood |
| CA2881321A1 (en) * | 2012-09-05 | 2014-03-13 | A1M Pharma Ab | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases |
| CA2885604A1 (en) * | 2012-09-09 | 2014-03-13 | Prothera Biologics, Inc. | Treatment of ischemia using inter-alpha inhibitor proteins |
| WO2015095553A1 (en) | 2013-12-20 | 2015-06-25 | Nephrogenesis, Llc | Methods and apparatus for kidney dialysis |
| EA039776B1 (ru) | 2016-03-18 | 2022-03-11 | Гард Терапьютикс Интернэшнл Айби | Новые белки, полученные из альфа-1-микроглобулина, и их применение |
| US20190314449A1 (en) * | 2016-11-16 | 2019-10-17 | The Board Of Regents Of The University Of Texas System | Cyclic dipeptides and wound healing |
| CA3081416A1 (en) | 2017-11-03 | 2019-05-09 | Guard Therapeutics International AB | Use of alpha-1-microglobulin for protection of bone marrow cells |
| JP6906807B2 (ja) | 2018-08-31 | 2021-07-21 | 一般社団法人クラインシュタイン医工学パースペクティブ | 透析装置 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166133A (en) | 1991-04-17 | 1992-11-24 | Cetus Corporation | Method for inhibing adhesion of white blood cells to endothelial cells |
| US6103691A (en) * | 1994-03-23 | 2000-08-15 | Tschesche; Harald | Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins |
| US5910482A (en) | 1996-03-19 | 1999-06-08 | Board Of Regents, The University Of Texas System | Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor |
| JP2001348342A (ja) | 2001-04-12 | 2001-12-18 | Nippon Zoki Pharmaceut Co Ltd | 免疫調整・抗炎症剤 |
| DE10125883A1 (de) | 2001-05-28 | 2002-12-12 | Serumwerk Bernburg Ag | Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie |
| DE10237423A1 (de) * | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
| US20070060512A1 (en) * | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
| AR045074A1 (es) * | 2003-07-23 | 2005-10-12 | Applied Research Systems | Uso de cd164 soluble en desordenes inflamatorios y autoinmunes |
| ITMI20032528A1 (it) * | 2003-12-19 | 2005-06-20 | Francesco Santangelo | Uso di cistina o di cisteina per la prevenzione e il |
| US20060105419A1 (en) | 2004-08-16 | 2006-05-18 | Biosite, Inc. | Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions |
| JP2007001922A (ja) | 2005-06-23 | 2007-01-11 | Asahi Kasei Pharma Kk | 透析患者における腎疾患改善剤、又は機能性食品 |
| US20070292421A1 (en) | 2005-07-28 | 2007-12-20 | Feinberg Bruce B | Method for treating preeclampsia |
| US20080133141A1 (en) | 2005-12-22 | 2008-06-05 | Frost Stephen J | Weighted Scoring Methods and Use Thereof in Screening |
| AU2008214837B2 (en) | 2007-02-12 | 2013-01-10 | A1M Pharma Ab | Diagnosis and treatment of preeclampsia |
-
2009
- 2009-07-17 EP EP09777272.7A patent/EP2313106B1/en active Active
- 2009-07-17 AU AU2009270435A patent/AU2009270435B2/en not_active Ceased
- 2009-07-17 ES ES09777272T patent/ES2571956T3/es active Active
- 2009-07-17 DK DK09777272.7T patent/DK2313106T3/en active
- 2009-07-17 CA CA2730531A patent/CA2730531A1/en not_active Abandoned
- 2009-07-17 EP EP13172049.2A patent/EP2638915B1/en not_active Not-in-force
- 2009-07-17 WO PCT/EP2009/005217 patent/WO2010006809A2/en active Application Filing
- 2009-07-17 HU HUE09777272A patent/HUE027953T2/en unknown
- 2009-07-17 US US13/054,188 patent/US10350268B2/en active Active
- 2009-07-17 PL PL09777272T patent/PL2313106T3/pl unknown
- 2009-07-17 PT PT131720492T patent/PT2638915T/pt unknown
- 2009-07-17 DK DK13172049.2T patent/DK2638915T3/en active
- 2009-07-17 HU HUE13172049A patent/HUE030274T2/en unknown
- 2009-07-17 JP JP2011517819A patent/JP5694928B2/ja not_active Expired - Fee Related
- 2009-07-17 ES ES13172049.2T patent/ES2614490T3/es active Active
- 2009-07-17 PL PL13172049T patent/PL2638915T3/pl unknown
-
2014
- 2014-11-21 JP JP2014236500A patent/JP6406987B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-10 JP JP2015241096A patent/JP6175478B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-29 HR HRP20160760TT patent/HRP20160760T1/hr unknown
- 2016-12-29 HR HRP20161808TT patent/HRP20161808T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012505154A (ja) | 2012-03-01 |
| AU2009270435B2 (en) | 2014-10-16 |
| US10350268B2 (en) | 2019-07-16 |
| WO2010006809A3 (en) | 2010-05-27 |
| JP6175478B2 (ja) | 2017-08-02 |
| JP2016102125A (ja) | 2016-06-02 |
| EP2638915B1 (en) | 2016-10-19 |
| CA2730531A1 (en) | 2010-01-21 |
| JP6406987B2 (ja) | 2018-10-17 |
| AU2009270435A1 (en) | 2010-01-21 |
| WO2010006809A2 (en) | 2010-01-21 |
| EP2638915A1 (en) | 2013-09-18 |
| PT2638915T (pt) | 2017-01-10 |
| PL2638915T3 (pl) | 2017-04-28 |
| EP2313106A2 (en) | 2011-04-27 |
| DK2638915T3 (en) | 2017-01-30 |
| ES2614490T3 (es) | 2017-05-31 |
| HUE030274T2 (en) | 2017-05-29 |
| ES2571956T3 (es) | 2016-05-27 |
| DK2313106T3 (en) | 2016-07-25 |
| PL2313106T3 (pl) | 2016-08-31 |
| US20110190208A1 (en) | 2011-08-04 |
| HUE027953T2 (en) | 2017-01-30 |
| HRP20160760T1 (hr) | 2016-08-12 |
| EP2313106B1 (en) | 2016-03-30 |
| JP2015071620A (ja) | 2015-04-16 |
| JP5694928B2 (ja) | 2015-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161808T1 (hr) | Medicinska uporaba hvatača radikala i antioksidansa alfa-1-mikroglobulin | |
| JP2012505154A5 (hr) | ||
| JP4969052B2 (ja) | 眼科用組成物 | |
| EA201071413A1 (ru) | Способ и композиция для лечения повышения внутриглазного давления и глаукомы | |
| NO20084199L (no) | Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom | |
| MX2010007295A (es) | Composiciones acuosas estables de ciclosporina. | |
| EA201190177A1 (ru) | Предмет одежды | |
| AR079706A1 (es) | Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso | |
| ATE511847T1 (de) | Pharmazeutische zubereitung für die behandlung entzündlicher erkrankungen des urogenitaltraktes | |
| WO2021126320A9 (en) | Treatment of amyotrophic lateral sclerosis and related disorders | |
| HUP0400548A2 (hu) | Belső szemnyomást csökkentő hatóanyag-kombinációk alkalmazása glaukoma kezelésére szolgáló gyógyszerkészítmények előállítására | |
| AR055591A1 (es) | Una composicion topica protectora de la piel y su uso | |
| BRPI0812494A2 (pt) | Derivados de 3',4',5-trimetóxi como estimulante da secreção de muco, método de preparação do mesmo, e composição farmacêutica compreendendo o mesmo | |
| NO20060651L (no) | Fremgangsmate for behandling av virale infeksjoner | |
| JP2017066065A (ja) | 眼科用組成物 | |
| AR064269A1 (es) | Formulaciones inhalantes de bisfosfonato y metodos para su utilizacion | |
| NZ602479A (en) | Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion | |
| DK1377164T3 (da) | Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo | |
| CY1110644T1 (el) | 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις | |
| Halsey et al. | Role of elastic fiber degradation in disease pathogenesis | |
| AR111166A1 (es) | Uso intradialítico de nitrito de sodio | |
| RU2007129571A (ru) | Композиции на основе солей гиалуроновой кислоты для лечения эпителиальных повреждений | |
| Gandorfer | Diffuse diabetic macular edema: pathology and implications for surgery | |
| DK1827403T3 (da) | Sammensætninger til behandling af sygdomme af øjenoverflader | |
| JP2012031184A (ja) | 眼科用組成物 |